Clinical Trial Update: Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer [Phase 2]

View source ↗

Summary

The document reports a Phase 2 clinical trial evaluating mirvetuximab soravtansine (IMGN853) in women with Folate Receptor-α positive endometrial cancer. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Mirvetuximab soravtansine (mirvetuximab soravtansine)

Snippet

Sponsor: Alessandro Santin | Conditions: Endometrial Cancer | Phase 2 | Status: RECRUITING